OTCPK:IVOB

Stock Analysis Report

Executive Summary

INVO Bioscience, Inc., a medical device company, provides novel solutions in assisted reproductive technologies to the reproductive health care community worldwide.

Snowflake

Fundamentals

Mediocre balance sheet and slightly overvalued.

Risks

  • INVO Bioscience has significant price volatility in the past 3 months.
  • INVO Bioscience is not covered by any analysts.

Share Price & News

How has INVO Bioscience's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-8.0%

OTCPK:IVOB

1.5%

US Medical Equipment

0.8%

US Market


1 Year Return

-31.2%

OTCPK:IVOB

9.7%

US Medical Equipment

1.9%

US Market

IVOB underperformed the Medical Equipment industry which returned 9.6% over the past year.

IVOB underperformed the Market in United States of America which returned 2.1% over the past year.


Share holder returns

IVOBIndustryMarket
7 Day-8.0%1.5%0.8%
30 Day-13.2%0.7%3.4%
90 Day-32.1%2.4%2.1%
1 Year-31.2%-31.2%10.6%9.7%4.2%1.9%
3 Year-16.7%-16.7%70.2%65.0%46.7%37.2%
5 Year461.2%461.2%136.0%109.1%62.3%44.5%

Price Volatility Vs. Market

How volatile is INVO Bioscience's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is INVO Bioscience undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

INVO Bioscience's share price is below the future cash flow value, and at a moderate discount (> 20%).

INVO Bioscience's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

INVO Bioscience is loss making, we can't compare its value to the US Medical Equipment industry average.

INVO Bioscience is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for INVO Bioscience, we can't assess if its growth is good value.


Price Based on Value of Assets

INVO Bioscience has negative assets, we can't compare the value of its assets to the US Medical Equipment industry average.


Next Steps

Future Growth

How is INVO Bioscience expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.1%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as INVO Bioscience has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of IVOB’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access INVO Bioscience's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has INVO Bioscience performed over the past 5 years?

9.8%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

INVO Bioscience does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.

Unable to compare INVO Bioscience's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare INVO Bioscience's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if INVO Bioscience has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.


Return on Assets

It is difficult to establish if INVO Bioscience has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if INVO Bioscience improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is INVO Bioscience's financial position?


Financial Position Analysis

INVO Bioscience is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

INVO Bioscience's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

INVO Bioscience has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.

Irrelevant to check if INVO Bioscience's debt level has increased considering it has negative shareholder equity.


Balance Sheet

Low level of unsold assets.

INVO Bioscience has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Whilst loss making INVO Bioscience has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.

Whilst loss making INVO Bioscience has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by -96.4% per year.


Next Steps

Dividend

What is INVO Bioscience's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate INVO Bioscience's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate INVO Bioscience's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as INVO Bioscience has not reported any payouts.

Unable to verify if INVO Bioscience's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as INVO Bioscience has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of INVO Bioscience's salary, the management and board of directors tenure and is there insider trading?

2.4yrs

Average management tenure


CEO

Katie Karloff (64yo)

11.7yrs

Tenure

US$143,000

Compensation

Ms. Kathleen T. Karloff, also known as Katie, co-founded INVO Bioscience in January 2007 and has been its Chairman of the Board and President since September 20, 2016 and has been its Chief Executive Offic ...


CEO Compensation Analysis

Katie's remuneration is lower than average for companies of similar size in United States of America.

Katie's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

2.4yrs

Average Tenure

61yo

Average Age

The tenure for the INVO Bioscience management team is about average.


Board Age and Tenure

2.4yrs

Average Tenure

61yo

Average Age

The average tenure for the INVO Bioscience board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

SellUS$27,050,00001 Feb 19
Claude Ranoux
EntityIndividual
Shares1,025,000
Max PriceUS$1,080.00

Ownership Breakdown


Management Team

  • Debra Hoopes (58yo)

    Acting Chief Executive Officer

    • Tenure: 0.08yrs
  • Katie Karloff (64yo)

    Chairman

    • Tenure: 11.7yrs
    • Compensation: US$143.00k
  • Rob Bowdring (61yo)

    Treasurer

    • Tenure: 6.5yrs
    • Compensation: US$143.00k
  • Kevin Doody (57yo)

    Medical Director & Director

    • Tenure: 2.4yrs
    • Compensation: US$179.00k
  • Mike Campbell (61yo)

    COO & Director

    • Tenure: 1.9yrs
    • Compensation: US$179.00k

Board Members

  • Katie Karloff (64yo)

    Chairman

    • Tenure: 11.7yrs
    • Compensation: US$143.00k
  • Steve Shum (48yo)

    Director

    • Tenure: 1.9yrs
    • Compensation: US$179.00k
  • Rob Bowdring (61yo)

    Treasurer

    • Tenure: 6.5yrs
    • Compensation: US$143.00k
  • Kevin Doody (57yo)

    Medical Director & Director

    • Tenure: 2.4yrs
    • Compensation: US$179.00k
  • Mike Campbell (61yo)

    COO & Director

    • Tenure: 1.9yrs
    • Compensation: US$179.00k

Company Information

INVO Bioscience, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: INVO Bioscience, Inc.
  • Ticker: IVOB
  • Exchange: OTCPK
  • Founded:
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$42.789m
  • Shares outstanding: 155.60m
  • Website: https://www.invobioscience.com

Number of Employees


Location

  • INVO Bioscience, Inc.
  • 407 Rear Mystic Avenue
  • Suite 34C
  • Medford
  • Massachusetts
  • 2155
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IVOBOTCPK (Pink Sheets LLC)YesNew Common StockUSUSDDec 2008

Biography

INVO Bioscience, Inc., a medical device company, provides novel solutions in assisted reproductive technologies to the reproductive health care community worldwide. Its lead product, INVOcell, is a novel m ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/18 00:07
End of Day Share Price2019/09/17 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.